GILD · News · 20261103N

Competition and Market Share Pressure

GILEAD SCIENCES, INC. · 2026-11-03 · Importance 40 · Surprise 42

Dr. Reddy’s received tentative USFDA approval for a generic HIV-prevention injectable, which it plans to make available for $40 per year in 120 countries outside the United States. The product is being supplied through a voluntary license from Gilead, expanding access while introducing a low-priced generic alternative in those markets. The report does not specify the product name.